Welcome to our dedicated page for Ascendis Pharma A/S SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ascendis Pharma A/S's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ascendis Pharma A/S's regulatory disclosures and financial reporting.
Ascendis Pharma A/S executive Shu Aimee, EVP & Chief Medical Officer, filed an initial Form 3 reporting equity holdings in the company. The filing lists direct holdings of restricted stock units (RSUs) convertible into 6,532, 3,197, and 9,552 ordinary shares, plus no directly held ordinary shares. Each RSU represents a right to receive one American Depositary Share, and each ADS represents one ordinary share. The RSUs vest beginning on March 1, 2027, with some grants vesting fully on that date and others in two or three equal annual installments starting then.
Ascendis Pharma A/S reported positive Week 52 topline results from New InsiGHTS, a Phase 2 clinical trial in the U.S. The study compared once-weekly TransCon hGH (lonapegsomatropin) with daily somatropin in prepubertal children with Turner syndrome.
The trial enrolled and dosed 49 children aged 1 to 10 years, who received either the weekly or daily growth hormone regimen. Doses for both treatments were then individualized based on IGF-1 levels to tailor therapy for each child.
Ascendis Pharma A/S reports new 104-week data from its pivotal ApproaCH Trial in children with achondroplasia treated once weekly with TransCon CNP (navepegritide). The data show children maintained consistent improvements in growth through Week 104, with further improvement in body proportionality during the second treatment year.
The randomized, double-blind, placebo-controlled trial enrolled 84 children aged 2–11 years, with a 52-week placebo-controlled phase followed by an open-label extension to Week 104. TransCon CNP, a prodrug of C-type natriuretic peptide, is designed for continuous CNP exposure to counter overactive FGFR3 signaling.
In February 2026, TransCon CNP was approved by the U.S. FDA under the trade name YUVIWEL to increase linear growth in pediatric patients 2 years and older with achondroplasia and open epiphyses. A Marketing Authorization Application for YUVIWEL is under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.
Ascendis Pharma A/S reports that its board granted 22,480 warrants to certain employees under its Articles of Association. Each warrant allows the holder to buy one ordinary share at an exercise price of US $240.52, matching the ADS closing price on the grant date.
Twenty-five percent of the warrants vest one year after the grant, with the remaining 75% vesting monthly over the following three years, subject to continued service and possible earlier vesting on certain exit events. After this grant, warrants to subscribe for an additional 1,644,153 shares remain available for future grants.
Ascendis Pharma A/S intends to sell 10,000 American Depositary Shares (ADS) by 03/05/2026. The filing lists the sale method as a warrant exercise for $2,400,000.00 and indicates trading on Nasdaq. The transaction type is listed as cash.
Ascendis Pharma A/S proposes sale of 94,000 American Depository Shares. The filing lists a warrant exercise by the issuer for 94,000 ADS on 03/05/2026 with cash consideration. The filing also records prior sales of 86,860 ADS by Jan Moller Mikkelsen on 01/13/2026.